Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US

Overview of attention for article published in Cost Effectiveness and Resource Allocation, January 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 39 Dimensions

Readers on

mendeley: 39 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 3,788 followers.

Our most recent pub in a great collaboration with @Mo_Safavi https://t.co/wxig7hWRph

Reply Repost Favourite

RT @Mo_Safavi: Latest pub from #RESP lab; Zafar is a gift that keeps on giving! https://t.co/0nbgmfcA03 Cost-effectiveness of tiotropium ve…

Reply Repost Favourite

Latest pub from #RESP lab; Zafar is a gift that keeps on giving! https://t.co/0nbgmfcA03 Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US https://t.co/0nbgmfcA03 #Asthma #Economics @CanRespirResNet @CORE_UBC

Reply Repost Favourite

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US https://t.co/ez2RhpOYMV https://t.co/pMcqn3bFKj

Reply Repost Favourite